摘要
目的:评价低分子肝素钙治疗对非小细胞肺癌化疗结局的影响。方法:60例非小细胞肺癌随机分为两组,低分子肝素钙治疗组为(DP+低分子肝素钙;非低分子肝素钙治疗组为单纯DP。60例非小细胞肺癌患者接受了多西紫杉醇联合顺铂(DP)方案化疗(多西紫杉醇75 mg/m^2,静脉滴注1 h;顺铂75 mg/m^2,静脉滴注2 h,每3周为1个周期,共4~6个周期),比较两组患者的一般资料、生存时间、凝血功能、出血事件。结果:低分子肝素治疗组的1年整体生存率(68.6%)、2年整体生存率(42.3%)、3年整体生存率(21.3%)均大于非肝素治疗组(分别为46.4%、20.5%、9.4%),低分子肝素治疗组治疗前后D-D、Fbg、PT、a PTT有统计学差异;非低分子肝素治疗组治疗前后D-D、Fbg、PT、a PTT无统计学差异;低分子肝素治疗组治疗后D-D、Fbg、PT、a PTT较非低分子肝素治疗组明显降低。低分子肝素钙治疗组和非肝素钙治疗的不良反应比较,差异无统计学意义(P>0.05)。结论:低分子肝素钙联合DP方案治疗非小细胞肺癌患者,可以改善其生存时间及凝血功能,疗效安全。
Objective To evaluate the effect of low molecular weight heparin treatment outcome of chemotherapy of non-small cell lung cancer. Method 60 cases of non-small cell lung cancer were randomly divided into two groups,low molecular weight heparin treatment group（ DP ＋ for low molecular weight heparin; low molecular weight heparin calcium in the treatment group than for pure DP. 60 cases of non small cell lung cancer patients accepted docetaxel plus cisplatin（ DP） chemotherapy（ docetaxel 75 mg/m2,intravenously 1 hour; cisplatin 75 mg/m2 intravenous drip of 2 hours,every 3 weeks for a cycle,a total of four to six cycles）,two groups of patients with general information,survival time,coagulation,bleeding events were compared. Results The low molecular weight heparin treatment group 1 year overall survival rate（ 68. 6%）,2 year overall survival rate（ 42. 3%）,3 years,the overall survival rate（ 21. 3%） were higher than that of non heparin treatment group（ 46. 4% 、20. 5% 、9. 4%,and low molecular weight heparin treatment group before and after treatment of D-D,Fbg,PT,a PTT,there wassignificant difference,low molecular weight heparin in the treatment of group before and after treatment of D-D,Fbg,PT,aP TT without significant difference; low molecular weight heparin in the treatment of treatment group after D-D,Fbg,PT,aP TT than non low molecular heparin in the treatment group decreased obviously. Adverse effects of low molecular weight heparin calcium treatment group and non heparin calcium in the treatment of no statistical difference（ P〈0. 05）. Conclusion Low molecular weight heparin calcium combined with DP regimen in the treatment of non small cell lung cancer patients can improve the survival time and coagulation function,efficacy and safety.
出处
《吉林医学》
CAS
2017年第1期61-64,共4页
Jilin Medical Journal
关键词
低分子肝素钙
非小细胞肺癌
化疗
Low-molecular-weight heparins calciurn
Nonsmall-cell lung cancer
Chemotherapy
